Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK
Adaptimmune Therapeutics (NASDAQ: ADAP) announced key executive departures as part of its ongoing restructuring efforts. Helen Tayton-Martin, Co-Founder and Chief Business & Strategy Officer, will leave on March 31, 2025, while CFO Gavin Wood will depart on May 31, 2025. These changes align with the company's previously announced 33% headcount reduction and target of $300 million in cost savings over four years.
The company plans to concentrate more corporate functions in the US. Tayton-Martin, who co-founded Adaptimmune in 2008, played a important role in growing the company from 5 to 300 employees and oversaw various strategic initiatives. Wood, who joined in 2020, led financial operations through successful financings and the approval of their first commercial product, Tecelra.
Adaptimmune Therapeutics (NASDAQ: ADAP) ha annunciato importanti dimissioni esecutive come parte dei suoi sforzi di ristrutturazione in corso. Helen Tayton-Martin, co-fondatrice e Chief Business & Strategy Officer, lascerà l'azienda il 31 marzo 2025, mentre CFO Gavin Wood partirà il 31 maggio 2025. Questi cambiamenti sono in linea con la riduzione del personale del 33% precedentemente annunciata e l'obiettivo di risparmiare 300 milioni di dollari in quattro anni.
L'azienda prevede di concentrare più funzioni aziendali negli Stati Uniti. Tayton-Martin, che ha co-fondato Adaptimmune nel 2008, ha svolto un ruolo importante nella crescita dell'azienda da 5 a 300 dipendenti e ha supervisionato varie iniziative strategiche. Wood, entrato nel 2020, ha guidato le operazioni finanziarie attraverso finanziamenti di successo e l'approvazione del loro primo prodotto commerciale, Tecelra.
Adaptimmune Therapeutics (NASDAQ: ADAP) anunció importantes salidas ejecutivas como parte de sus esfuerzos de reestructuración en curso. Helen Tayton-Martin, cofundadora y directora de negocios y estrategia, dejará la empresa el 31 de marzo de 2025, mientras que CFO Gavin Wood se marchará el 31 de mayo de 2025. Estos cambios están en línea con la reducción de personal del 33% anunciada anteriormente y el objetivo de $300 millones en ahorros en cuatro años.
La empresa planea concentrar más funciones corporativas en EE. UU. Tayton-Martin, que cofundó Adaptimmune en 2008, desempeñó un papel importante en el crecimiento de la empresa de 5 a 300 empleados y supervisó varias iniciativas estratégicas. Wood, quien se unió en 2020, lideró las operaciones financieras a través de financiamientos exitosos y la aprobación de su primer producto comercial, Tecelra.
Adaptimmune Therapeutics (NASDAQ: ADAP)는 ongoing 재구성 노력의 일환으로 주요 임원 이탈을 발표했습니다. 헬렌 테이튼-마틴 공동 창립자 및 최고 사업 및 전략 책임자가 2025년 3월 31일에 퇴사하며, CFO 가빈 우드는 2025년 5월 31일에 퇴사합니다. 이러한 변화는 회사가 이전에 발표한 33% 인력 감축 및 4년 동안 3억 달러 비용 절감 목표와 일치합니다.
회사는 미국에 더 많은 기업 기능을 집중할 계획입니다. 2008년에 Adaptimmune을 공동 설립한 Tayton-Martin은 회사를 5명에서 300명으로 성장시키는 데 중요한 역할을 했으며, 여러 전략적 이니셔티브를 감독했습니다. 2020년에 합류한 Wood는 성공적인 자금 조달과 첫 상업 제품인 Tecelra의 승인 과정을 주도했습니다.
Adaptimmune Therapeutics (NASDAQ: ADAP) a annoncé des départs clés parmi ses dirigeants dans le cadre de ses efforts de réorganisation en cours. Helen Tayton-Martin, co-fondatrice et responsable des affaires et de la stratégie, quittera l'entreprise le 31 mars 2025, tandis que CFO Gavin Wood partira le 31 mai 2025. Ces changements s'inscrivent dans le cadre de la réduction de 33 % des effectifs déjà annoncée et de l'objectif d'économiser 300 millions de dollars sur quatre ans.
L'entreprise prévoit de concentrer davantage de fonctions d'entreprise aux États-Unis. Tayton-Martin, qui a cofondé Adaptimmune en 2008, a joué un rôle important dans la croissance de l'entreprise de 5 à 300 employés et a supervisé diverses initiatives stratégiques. Wood, qui a rejoint l'entreprise en 2020, a dirigé les opérations financières grâce à des financements réussis et à l'approbation de leur premier produit commercial, Tecelra.
Adaptimmune Therapeutics (NASDAQ: ADAP) hat wichtige Veränderungen im Management angekündigt, die Teil ihrer laufenden Umstrukturierungsbemühungen sind. Helen Tayton-Martin, Mitgründerin und Chief Business & Strategy Officer, wird das Unternehmen am 31. März 2025 verlassen, während CFO Gavin Wood am 31. Mai 2025 ausscheiden wird. Diese Änderungen stehen im Einklang mit der zuvor angekündigten Reduzierung des Personalbestands um 33 % und dem Ziel, in vier Jahren 300 Millionen Dollar einzusparen.
Das Unternehmen plant, mehr Unternehmensfunktionen in den USA zu konzentrieren. Tayton-Martin, die Adaptimmune 2008 mitbegründete, spielte eine wichtige Rolle beim Wachstum des Unternehmens von 5 auf 300 Mitarbeiter und überwachte verschiedene strategische Initiativen. Wood, der 2020 eintrat, leitete die Finanzoperationen durch erfolgreiche Finanzierungen und die Genehmigung ihres ersten Handelsprodukts, Tecelra.
- Target of $300 million in cost savings over next four years
- Recent approval of first commercial product, Tecelra
- Strategic consolidation of operations in US market
- 33% workforce reduction
- Loss of two key executive leaders
- Significant organizational restructuring indicating potential operational challenges
Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31, 2025
Gavin Wood, Chief Financial Officer, will step down from the Company May 31, 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 19, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that two of its executive leadership team members based in the UK will leave the Company next year. As previously announced, Adaptimmune is reducing its headcount by
Adrian Rawcliffe, Adaptimmune's Chief Executive Officer:
"I want to pay tribute to Helen who has been an integral part of Adaptimmune since she co-founded the Company in 2008. She oversaw Adaptimmune's transition from 5 to 300 colleagues through transatlantic expansion, clinical, academic and commercial collaborations and private and public financing through IPO. Likewise, Gavin has made substantial contributions since joining the Company in 2020. He has led our financial strategy and operations through successful financings and a period of profound change including the approval of our first commercial product, Tecelra, this year."
Helen Tayton-Martin, Ph.D., M.B.A. co-founded Adaptimmune from the former company, Avidex Limited, where she was responsible for business development of the soluble TCR program in cancer and HIV from 2005 to 2008. She has been an integral part of Adaptimmune, serving in various leadership roles over the years and executing multiple partnerships. Since October 2022, Dr. Tayton-Martin has served as Adaptimmune's Chief Business & Strategy Officer with responsibility for optimizing the strategic and commercial opportunity for the Company's assets, leading on business development, competitive intelligence and alliance management. Dr. Tayton-Martin has more than 30 years of experience working within the pharma, biotech and consulting environment in disciplines across preclinical and clinical development, outsourcing, strategic planning, due diligence, business development and company operations.
Gavin Wood has served as Adaptimmune's Chief Financial Officer since April 2020 and has led the Company's financial operations and investor relations. Gavin has developed a first-class finance and procurement team during his tenure at Adaptimmune as well as formulating and executing against the Company's financial strategy including raising significant capital through BD, equity and debt. Gavin joined Adaptimmune following a career in life science finance that has included CFO roles with Abcam Plc (LSE: ABC) and Affymetrix Inc (NASDAQ: AFFX).
About Adaptimmune
Adaptimmune is a fully integrated cell therapy company working to redefine how cancer is treated. With its unique engineered T cell receptor (TCR) platform, the Company is developing personalized medicines designed to target and destroy difficult-to-treat solid tumor cancers and to radically improve the patient's cancer treatment experience.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended 31 December, 2023, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
Investor Relations
Juli P. Miller, Ph.D. - VP, Corporate Affairs and Investor Relations
T : +1 215 825 9310
M : +1 215 460 8920
Juli.Miller@adaptimmune.com
Media Relations
Dana Lynch, Senior Director of Corporate Communications
M: +1 267 990 1217
Dana.Lynch@adaptimmune.com
###
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/234299
FAQ
When will Helen Tayton-Martin leave Adaptimmune (ADAP)?
What cost savings is Adaptimmune (ADAP) targeting in its restructuring?
How many employees is Adaptimmune (ADAP) laying off in its restructuring?
When did Adaptimmune (ADAP) receive approval for Tecelra?
When will CFO Gavin Wood leave Adaptimmune (ADAP)?
